Dutasteride
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Dutasteride
- Dutasteride: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita
Dutasteride: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita
One-Sentence Summary
Dutasteride is a 5-alpha reductase inhibitor. The registration data supplied lists no approved indication, but the drug is generally used for androgen-driven conditions such as benign prostatic hyperplasia, and this should be confirmed against the SAHPRA Professional Information (PI). The TxGNN model predicts it may be effective for Ambras type hypertrichosis universalis congenita, with 0 clinical trials and 0 publications supporting this direction. The prediction is model-only and the mechanistic link is weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA registration data (benign prostatic hyperplasia is the usual use; confirm against the PI) |
| Predicted New Indication | Ambras type hypertrichosis universalis congenita |
| TxGNN Prediction Score | 99.998% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Dutasteride inhibits 5-alpha reductase types 1 and 2 and lowers dihydrotestosterone (DHT). Detailed mechanism-of-action data from DrugBank is not available in this pack, so the description above comes from the pack’s mechanistic assessment.
Ambras syndrome is a congenital condition caused by chromosomal rearrangements affecting TRPS1 regulation at 8q22. It is not primarily androgen-driven, so lowering DHT has no clear reason to help. The very high TxGNN score reflects a pattern in the knowledge graph. It may simply capture the drug’s known association with hair-related conditions, possibly in the opposite direction (reducing hair growth rather than increasing it). Without clinical evidence, the score should not be read as support for efficacy.
Other Predictions Reviewed
None of the other top-10 predictions has supporting trial evidence. All are rated “Hold”.
| Rank | Predicted Indication | Score | Evidence Level | Assessment |
|---|---|---|---|---|
| 2 | Hypertrichosis | 99.997% | L5 | Indirect link only. Hypertrichosis is largely androgen-independent. |
| 3 | Malformation syndrome with odontal/periodontal component | 99.997% | L5 | No credible link. The 20 retrieved papers concern periodontitis in general and none evaluates dutasteride. |
| 4 | Syndrome with Dandy-Walker malformation | 99.996% | L5 | No plausible link. Likely a graph artefact. |
| 5 | Isolated genetic hair shaft abnormality | 99.996% | L5 | Structural defect not driven by DHT. |
| 6 | Hypotrichosis simplex of the scalp | 99.771% | L5 | Genetic, not DHT-mediated. Cannot extrapolate from androgenetic alopecia. |
| 7 | Congenital hypotrichosis milia | 99.753% | L5 | No known androgen-dependent mechanism. |
| 8 | Diffuse alopecia areata | 99.675% | L4 | Autoimmune. The one retrieved paper is a review of androgenetic alopecia in women and is a disease mismatch. |
| 9 | Migraine with brainstem aura | 99.667% | L5 | Speculative link through neurosteroids. |
| 10 | Familial isolated trichomegaly | 99.565% | L5 | Mechanism not established as androgen-dependent. |
Clinical Trial Evidence
Currently no related clinical trials registered. No ClinicalTrials.gov, SANCTR, PACTR or ICTRP trials were retrieved for this prediction.
Literature Evidence
Currently no related literature available for the top-ranked prediction.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 55/21.12/0032 | Swifsul | Capsule | Not stated in the data |
| Reg. No. 44/21.12/0850 | Duodart 0.5mg/0.4mg | Capsule (oral) | Not stated in the data |
The Essential Medicines List (EML) status was not provided. Approved indication text should be taken from the SAHPRA package inserts.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone (L5), with no trials or drug-specific literature. The biological link between DHT suppression and Ambras syndrome is weak. All ten predicted indications are also on hold.
To proceed, the following is needed:
- SAHPRA package insert data (approved indications, warnings, contraindications), because the missing safety data blocks safety screening
- Mechanism-of-action data from DrugBank
- Disease-specific preclinical or clinical evidence linking 5-alpha reductase inhibition to the predicted condition
- A review of whether the model score reflects the opposite direction of effect (hair reduction rather than growth)
- A route-compatibility assessment against the predicted indication
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.